Hirayama disease: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
Hirayama Disease | == Hirayama Disease == | ||
Hirayama disease, also known as monomelic amyotrophy, is a rare neurological | |||
[[File:Modern_3T_MRI.JPG|thumb|right|Modern 3T MRI machine used for diagnosing Hirayama disease]] | |||
'''Hirayama disease''', also known as monomelic amyotrophy, is a rare neurological disorder characterized by muscle weakness and atrophy in the distal upper limbs. It predominantly affects young males and is considered a type of motor neuron disease. | |||
== Pathophysiology == | == Pathophysiology == | ||
Hirayama disease is believed to be caused by a dynamic compression of the cervical spinal cord during neck flexion. This compression leads to ischemia and subsequent damage to the anterior horn cells, which are responsible for innervating the muscles of the hand and forearm. | |||
== Clinical Presentation == | |||
Patients with Hirayama disease typically present with insidious onset of unilateral or asymmetric weakness and atrophy of the hand and forearm muscles. The condition is often painless and progresses slowly over several years before stabilizing. | |||
== Diagnosis == | == Diagnosis == | ||
The diagnosis of Hirayama disease is primarily clinical, supported by imaging studies. [[Magnetic resonance imaging|MRI]] of the cervical spine is crucial for diagnosis, as it can demonstrate the forward displacement of the posterior dural sac and the loss of attachment to the vertebral bodies during neck flexion. | |||
== Treatment == | == Treatment == | ||
There is no cure for Hirayama disease | |||
There is no definitive cure for Hirayama disease. Management focuses on preventing further progression and alleviating symptoms. Patients are often advised to avoid neck flexion and may be fitted with a cervical collar. Physical therapy can help maintain muscle strength and function. | |||
== Prognosis == | == Prognosis == | ||
The prognosis for Hirayama disease is generally favorable, with many patients experiencing stabilization of symptoms after a few years. However, some degree of muscle weakness and atrophy may persist. | The prognosis for Hirayama disease is generally favorable, with many patients experiencing stabilization of symptoms after a few years. However, some degree of muscle weakness and atrophy may persist. | ||
== | |||
== Related Pages == | |||
* [[ | * [[Motor neuron disease]] | ||
* [[ | * [[Spinal cord]] | ||
* [[ | * [[Muscle atrophy]] | ||
[[Category:Neurological disorders]] | |||
[[Category: | |||
Revision as of 11:33, 15 February 2025
Hirayama Disease
Hirayama disease, also known as monomelic amyotrophy, is a rare neurological disorder characterized by muscle weakness and atrophy in the distal upper limbs. It predominantly affects young males and is considered a type of motor neuron disease.
Pathophysiology
Hirayama disease is believed to be caused by a dynamic compression of the cervical spinal cord during neck flexion. This compression leads to ischemia and subsequent damage to the anterior horn cells, which are responsible for innervating the muscles of the hand and forearm.
Clinical Presentation
Patients with Hirayama disease typically present with insidious onset of unilateral or asymmetric weakness and atrophy of the hand and forearm muscles. The condition is often painless and progresses slowly over several years before stabilizing.
Diagnosis
The diagnosis of Hirayama disease is primarily clinical, supported by imaging studies. MRI of the cervical spine is crucial for diagnosis, as it can demonstrate the forward displacement of the posterior dural sac and the loss of attachment to the vertebral bodies during neck flexion.
Treatment
There is no definitive cure for Hirayama disease. Management focuses on preventing further progression and alleviating symptoms. Patients are often advised to avoid neck flexion and may be fitted with a cervical collar. Physical therapy can help maintain muscle strength and function.
Prognosis
The prognosis for Hirayama disease is generally favorable, with many patients experiencing stabilization of symptoms after a few years. However, some degree of muscle weakness and atrophy may persist.
